Andrew Dorr, M.D.

Andrew Dorr, M.D. is a medical oncologist with a long history of successful cancer drug development with leadership roles in the development of Eulexin^® (flutamide) in prostate cancer, Taxol^® (paclitaxel) in breast cancer, Gemzar^® (gemcitabine) in pancreatic and non-small cell lung cancers, Alimta^® (pemetrexed) in NSCLC and mesothelioma, Treanda^® (bendamustine) in chronic lymphocytic leukemia and non-Hodgkin lymphoma, Avastin^® (bevacizumab) in glioblastoma and Talzenna^® (talazoparib) in BRCA mutant breast cancer.  He was also instrumental in the design and leadership of the Tamoxifen Breast Cancer Prevention study, serving on the Steering Committee.

Dr. Dorr has had a successful consulting practice in cancer drug development since 2005.  Previously, he served as Chief Operating Officer at Salmedix Inc., Chief Medical Officer at Isis (now Ionis) Pharmaceuticals, Inc. and as Medical Research Advisor at Eli Lilly & Company where he was responsible for strategic development of Lilly’s cancer pipeline from pre-clinical through Phase III. Previously, at the National Cancer Institute, he was responsible for NCI-funded national clinical trial programs in breast, prostate, kidney, bladder and testicular cancers, as well as melanoma.

Dr. Dorr has over 70 cancer therapeutic publications. Dr. Dorr received his B.S. degree from Davidson College and his M.D. from the University of North Carolina at Chapel Hill.  In the last several years, Dr. Dorr has served as Chief Medical Officer for a variety of relatively to completely virtual companies, conducting first-in-human trials and planning pivotal trials based on the results in these studies.  These companies have included Vivace Therapeutics, Virtuoso Therapeutics, Fortis Therapeutics, PIC Therapeutics, Curegenix, Phoenix Molecular Designs, Circle Pharmaceuticals, BrightPath BioTherapeutics and Orphagen Pharmaceuticals.